J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies
Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with…
The Download: What’s next for AI, and stem-cell therapies
For the last couple of years we’ve had a go at predicting what’s coming next in AI. A…
Amgen: Blockbusters, Emerging Therapies, And Investment Potential (NASDAQ:AMGN)
This article was written by Follow Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years…
Stem-cell therapies that work: 10 Breakthrough Technologies 2025
The epilepsy trial, from a company called Neurona Therapeutics, is at an early stage—only 15 patients have been…